ProPhase Labs, Inc. Convertible Debt, Current
ProPhase Labs, Inc. (PRPH) had Convertible Debt, Current of $438.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Debt, Current › Long-Term Debt and Lease Obligation, Current
us-gaap:ConvertibleDebtCurrent · last filed 2026-08-19
- 2026-06-30: Convertible Debt, Current $438.00K.
- 2026-03-31: Convertible Debt, Current $304.00K.
- 2025-12-31: Convertible Debt, Current $244.00K.
- 2025-09-30: Convertible Debt, Current $517.00K.
| Period end | Convertible Debt, Current |
|---|---|
| 2026-06-30 | $438.00K 10-Q · filed 2026-08-19 |
| 2026-03-31 | $304.00K 10-Q/A · filed 2026-07-09 |
| 2025-12-31 | $244.00K 10-Q · filed 2026-08-19 |
| 2025-09-30 | $517.00K 10-Q · filed 2025-11-19 |
| 2024-12-31 | $0.00 10-K · filed 2026-06-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |